Pharma giant Zydus Cadila said it received final approval from the US Food and Drug Administration to sell a skin ointment and an ulcer tablet in the country.
Ointment Nystatin is used to treat fungal skin infections and will be manufactured at the group’s Topical manufacturing facility at Ahmedabad.
Capsule Omeprazoleand Sodium Bicarbonate is used to treat stomach and esophagus (food pipe) related issues such asacid reflux and ulcers.
They will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
With this, said Zydus, the group now has more than 190 approvals out of the 320 generic applications it has filed.
The company develops, manufactures and markets a broad range of healthcare therapies.
It is headquartered at Ahmedabad in Gujarat and employs over 21,000 people worldwide.
It is the fourth largest pharmaceutical company in India.
Cadila was founded in 1952 by Ramanbhai Patel (1925–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi.
In 1995 the Patel and Modi families split, with the Modi family’s share being moved into a new company called Cadila Pharmaceuticals Ltd. and Cadila Healthcare became the Patel family’s holding company.
In 2015, Cadila Healthcare acquired German Remedies.